RESEARCH TRIANGLE PARK – A new report from Crunchbase finds that North Carolina is the state with the second-highest increase, on a percentage basis, in venture capital invested in startup companies, behind Michigan, between 2016 and 2020.
According to the data from Crunchbase, North Carolina firms brought in $4.1 billion in 2020, compared to $800 million in 2016, which is nearly a 410 percent increase.
Of course, Epic Games raised $1.5 billion in 2020 in one mega-round, and AvidXchange raised a combined $572 million.
Let’s not forget the rapid rise of nCino in Wilmington (now public) and other unicorns such as Raleigh-based Pendo.
Without large funding rounds, North Carolina’s totals, and its rank among the states, look a little bit different.
Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix
Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease
. | April 28, 2021
Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.
More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates as high as 30-80% across infection types
i. Fosmanogepix has a novel mechanism of action with the potential to target fungal strains resistant to standard of care therapy. As there are only three classes of antifungal medications currently available, antifungal resistance can severely limit treatment options; a potential new therapeutic class may therefore be of impo
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Pfizer Acquires Amplyx Pharmaceuticals
Opportunity to advance Pfizer s expertise and deep heritage in infectious disease
NEW YORK Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx s lead compound, Fosmanogepix (APX001), is a novel investigational asset
Pfizer Acquires Amplyx Pharmaceuticals investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.